PER-004-99已完成未知
A DOUBLE BLIND COMPARISON OF THE EFFECTS OF AMLODIPINE AND ENALAPRIL ON INSULIN SENSITIVITY IN HYPERTENSIVE PATIENTS
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- PFIZER S.A.,
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •a) The patient has consented to participate in accordance with the relevant provisions of the Helsinki Declaration (Appendix B).
- •b) Patients of both sexes> 18 and <80 years with a recent diagnosis or history of essential hypertension.
- •c) Outpatients diagnosed with mild and moderate hypertension defined as:
- •1) an average of the diastolic blood pressure (DBP) measurements> 90 and <110 mmHg (without antihypertensive medication) in the sitting position. The mean blood pressure will be documented twice with a minimum difference of 1 week and without antihypertensive medication (the difference between the averages should not be more than 10 mmHg). 1. Diuretic agents should be discontinued at least 1 week before the Placebo Phase; and 2) baseline daytime mean of ambulatory PAD> 85 mmHg.
排除标准
- •a) Pregnant or lactating women and those with pregnancy potential.
- •b) Concomitant treatment with other antihypertensive drugs or other drugs that could alter blood pressure, or oral anticoagulants. Patients who are under previous antihypertensive treatment should only be included in the study if the Investigator considers that the suspension of previous antihypertensive therapy would not be dangerous.
- •c) Intermittent or unstable hypertension; Systolic BP (SBP)> 200 mmHg or DBP> 115 mmHg in two consecutive weekly visits.
- •d) Malignant or accelerated hypertension (Retinopathy Grade IV)
- •e) History of secondary hypertension, such as (1) Hyperaldosteronism; (2) Pheochromocytoma; (3) Renal artery stenosis; (4) Aortic coarctation; (5) Cushing´s disease or syndrome; (6) Drugs as oral contraceptives. f) Hematological, hepatic or major cardiac disease; myocardial infarction or cerebrovascular accident in the 6 months prior to study entry; ischemic heart disease that requires the use of anti-ischemic drugs (beta-blockers, calcium blockers or nitrates); concurrent or previous evidence of heart failure; clinically significant abnormalities of cardiac conduction, Wolf Parkinson White Syndrome, second and third degree AV block; serum creatinine> 1.5 mg / dl; presence of clinically significant abnormalities in laboratory tests of liver function (TOO, TGP) that exceed 2 times the normal higher value.
- •g) Patients presenting with angina pectoris with Functional Class NYHA> II.
- •h) Greater metabolic or endocrine disease.
- •i) History of chronic diarrhea, peptic ulcer, gastrectomy, or any other intestinal condition that may affect the absorption of the study drug.
- •j) History of asthma, eczema, proven allergy or intolerance to inhibitory drugs of the EGA or calcium blockers.
- •k) Terminal illness or other condition that prevents the completion and evaluation of the therapy of the drugs under study.
- •1) History of alcohol or drug abuse, psychosis, antagonistic personality, low motivation or any other emotional or intellectual problem that could invalidate the written consent, or limit the patient´s ability to comply with the requirements of the protocol.
- •m) Participation in any other study that involves research or sale products concomitantly or within the month prior to entering the study.
研究者
相似试验
尚未招募
2 期
A Study to compare the effect of Erandmooladi enema therapy with sand sudation and Erandmooladi enema therapy with Oral medicine in the Management of Rheumatoid arthritisCTRI/2023/04/051961Dr Daljit Kaur
尚未招募
不适用
effect of two different resin-based temporary crown materials and methods on gum health- A clinical studyCTRI/2022/10/046139Dr Raisa Chodankar
进行中（未招募）
不适用
A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA (PCA), IN PATIENTS SUFFERING MODERATE TO SEVERE POST-OPERATIVE PAIN REQUIRING PCA FOR AT LEAST 24 HOURS - N/AEUCTR2005-001690-99-CZCeNeS Ltd
进行中（未招募）
1 期
A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA (PCA), IN PATIENTS SUFFERING MODERATE TO SEVERE POST-OPERATIVE PAIN REQUIRING PCA FOR AT LEAST 24 HOURS - N/AEUCTR2005-001690-99-GBCeNeS Ltd480
进行中（未招募）
不适用
A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA (PCA), IN PATIENTS SUFFERING MODERATE TO SEVERE POST-OPERATIVE PAIN REQUIRING PCA FOR AT LEAST 24 HOURS - N/AEUCTR2005-001690-99-DECeNeS Ltd